Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. / Huynh, Kim; Klose, Marianne; Krogsgaard, Kim; Drejer, Jørgen; Byberg, Sarah; Madsbad, Sten; Magkos, Faidon; Aharaz, Abdellatif; Edsberg, Berit; Tfelt-Hansen, Jacob; Astrup, Arne; Feldt-Rasmussen, Ulla.
In: European Journal of Endocrinology, Vol. 186, No. 6, 2022, p. 687-700.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
AU - Huynh, Kim
AU - Klose, Marianne
AU - Krogsgaard, Kim
AU - Drejer, Jørgen
AU - Byberg, Sarah
AU - Madsbad, Sten
AU - Magkos, Faidon
AU - Aharaz, Abdellatif
AU - Edsberg, Berit
AU - Tfelt-Hansen, Jacob
AU - Astrup, Arne
AU - Feldt-Rasmussen, Ulla
N1 - CURIS 2022 NEXS 130
PY - 2022
Y1 - 2022
N2 - Context: Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective.Objective: Investigate the safety and efficacy of Tesomet (0.5mg tesofensine/50mg metoprolol) in adults with hypothalamic obesity.Methods: Twenty-one adults with hypothalamic obesity (16 females) were randomized to Tesomet (0.5mg/50mg) or placebo for 24 weeks. Patients also received diet/lifestyle counselling. The primary endpoint was safety; secondary endpoints included measures of body weight, appetite-scores, quality of life, and metabolic profile.Results: Eighteen patients completed 24-weeks. Consent withdrawal, eligibility, and serious adverse events (SAE) unrelated to treatment resulted in dropouts. One patient experienced a Tesomet-related SAE of exacerbated pre-existing anxiety leading to treatment discontinuation. Tesomet-related adverse events were otherwise mostly mild, and included sleep disturbances (Tesomet 50%, Placebo 13%), dry mouth (Tesomet 43%, Placebo 0%), and headache (Tesomet 36%, Placebo 0%). No significant differences in heart rate or blood pressure were observed between groups. Compared to placebo, Tesomet resulted in additional mean (95% CI) weight change of -6.3% ([-11.3; -1.3]; P = 0.017), increased the number of patients achieving ≥5% weight loss (Tesomet 8/13, Placebo 1/8; P = 0.046), and tended to augment the reduction in waist circumference by 5.7cm ([-0.1; 11.5]; P = 0.054).Conclusion: Tesomet was well-tolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.
AB - Context: Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective.Objective: Investigate the safety and efficacy of Tesomet (0.5mg tesofensine/50mg metoprolol) in adults with hypothalamic obesity.Methods: Twenty-one adults with hypothalamic obesity (16 females) were randomized to Tesomet (0.5mg/50mg) or placebo for 24 weeks. Patients also received diet/lifestyle counselling. The primary endpoint was safety; secondary endpoints included measures of body weight, appetite-scores, quality of life, and metabolic profile.Results: Eighteen patients completed 24-weeks. Consent withdrawal, eligibility, and serious adverse events (SAE) unrelated to treatment resulted in dropouts. One patient experienced a Tesomet-related SAE of exacerbated pre-existing anxiety leading to treatment discontinuation. Tesomet-related adverse events were otherwise mostly mild, and included sleep disturbances (Tesomet 50%, Placebo 13%), dry mouth (Tesomet 43%, Placebo 0%), and headache (Tesomet 36%, Placebo 0%). No significant differences in heart rate or blood pressure were observed between groups. Compared to placebo, Tesomet resulted in additional mean (95% CI) weight change of -6.3% ([-11.3; -1.3]; P = 0.017), increased the number of patients achieving ≥5% weight loss (Tesomet 8/13, Placebo 1/8; P = 0.046), and tended to augment the reduction in waist circumference by 5.7cm ([-0.1; 11.5]; P = 0.054).Conclusion: Tesomet was well-tolerated, did not affect heart rate or blood pressure, and resulted in significant reductions in body weight compared to placebo in adults with hypothalamic obesity.
U2 - 10.1530/EJE-21-0972
DO - 10.1530/EJE-21-0972
M3 - Journal article
C2 - 35294397
VL - 186
SP - 687
EP - 700
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
SN - 0804-4643
IS - 6
ER -
ID: 300758930